 |
|
|
| |
IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
S. WEINHEIMER1, C. MARSOLAIS2, Z. COHEN2, S. LEWIS1
1TaiMed Biologics, Irvine, CA, 2Theratechnologies, Montreal, Canada.
"Patients receiving their current failing ARV therapy, or no therapy, were monitored during a 7-day control period. Thereafter, a loading dose of 2,000 mg of intravenous (IV) IBA was the only ARV agent added to their regimen for 7 days. IBA was continued at doses of 800 mg IV every 2 weeks through 24 weeks on study treatment."
|
| |
|
|
|
|
|
